Karolinska Outcomes Registry
SITE-OBS-PMR-001-003
ClosedHealthy · 3
Enrolled
980
Screen fail %
0.0%
Open queries
0
Risk score
7
Months active
72
Study assignment
- Sponsor
- Veridian Pharma
- Study code
- OBS-PMR-001
- Therapeutic area
- Post-marketing / Real-world
- Indication
- Long-term safety surveillance of verexitide in T2DM
Staffing
- Principal investigator
- Dr. Anders Lindqvist
- Site coordinator
- Stockh Site Coordinator
- Monitor (CRA)
- CRA — Sweden region
Recent activity
| Date | Kind | Summary | Actor |
|---|---|---|---|
| 2026-09-10 | Enrollment | New subject enrolled (Subject 0042) | Dr. Anders Lindqvist |
| 2026-09-07 | Monitoring visit | CRA monitoring visit completed; 12 SDV checks closed | CRA team |
| 2026-09-03 | Query resolved | Two open queries resolved by site coordinator | Site coordinator |
| 2026-08-29 | Signature | Protocol amendment v3 signed by PI | Dr. Anders Lindqvist |
| 2026-08-22 | Query opened | Data management opened query on AE form (Subject 0031) | Data management |
Deviation history
| Date | Severity | Title | CAPA | Status |
|---|---|---|---|---|
| 2026-08-13 | minor | Informed consent re-consent window exceeded | Site retrained on v3 protocol; tracker added. | open |